Taikang Asset Management (Hong Kong) CO LTD Bei Gene, Ltd. Transaction History
Taikang Asset Management (Hong Kong) CO LTD
- $715 Million
- Q1 2025
A detailed history of Taikang Asset Management (Hong Kong) CO LTD transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Taikang Asset Management (Hong Kong) CO LTD holds 7,000 shares of BGNE stock, worth $1.59 Million. This represents 0.22% of its overall portfolio holdings.
Number of Shares
7,000Holding current value
$1.59 Million% of portfolio
0.22%Shares
2 transactions
Others Institutions Holding BGNE
# of Institutions
291Shares Held
36.3MCall Options Held
111KPut Options Held
112K-
Baker Bros. Advisors LP New York, NY8.8MShares$1.99 Billion23.78% of portfolio
-
Capital International Investors Los Angeles, CA5.09MShares$1.15 Billion0.24% of portfolio
-
Primecap Management CO Pasadena, CA5.06MShares$1.15 Billion0.97% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.71MShares$615 Million0.09% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E91.03MShares$234 Million7.2% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...